Dimerix (ASX:DXB) Total Equity: A$-1.68 Mil (As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.19
! 3 Warning Signs
View Full Analysis

What is Dimerix Total Equity?

Dimerix ASX:DXB -5.00% 32 Total Equity is A$-1.68 Mil as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Dimerix's total equity for the quarter that ended in Dec. 2025 was A$-1.68 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Dimerix Total Equity Historical Data

* Premium members only.

The historical data trend for Dimerix's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix Total Equity Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 14.42 5.96 18.19 13.38

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 18.19 7.17 13.38 -1.68
ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Dimerix's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=91.177-77.798
=13.38

Dimerix's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=64.561-66.242
=-1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$-1.68 Mil mean?
Dimerix (ASX:DXB) has a Total Equity of A$-1.68 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Dimerix and its competitors.
Is Dimerix's Total Equity too high?
Dimerix's current Total Equity is A$-1.68 Mil. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Total Equity compare to VRTX and REGN?
Dimerix's Total Equity of A$-1.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Dimerix and its competitors. Dimerix's current Total Equity is A$-1.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Total Equity of A$-1.68 Mil. The current Total Equity is A$-1.68 Mil. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Total Equity is A$-1.68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.19
Price